We are live on ! Find out more
SNDX icon

Syndax Pharmaceuticals
SNDX

210 hedge funds and large institutions have $1.71B invested in Syndax Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 38 funds opening new positions, 86 increasing their positions, 58 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

58% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 24

48% more repeat investments, than reductions

Existing positions increased: 86 | Existing positions reduced: 58

7% more funds holding

Funds holding: 196 → 210 (+14)

1.76% more ownership

Funds ownership: 102.79% → 104.55% (+1.8%)

9% more call options, than puts

Call options by funds: $16.2M | Put options by funds: $14.9M

4% less capital invested

Capital invested by funds: $1.79B → $1.71B (-$80M)

18% less funds holding in top 10

Funds holding in top 10: 11 → 9 (-2)

Holders
210
Holders Change
+14
Holders Change %
+7.14%
% of All Funds
3.02%
Holding in Top 10
9
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-18.18%
% of All Funds
0.13%
New
38
Increased
86
Reduced
58
Closed
24
Calls
$16.2M
Puts
$14.9M
Net Calls
+$1.27M
Net Calls Change
-$2.89M

Top Buyers

1
BNP Paribas Asset Management
BNP Paribas Asset Management
France
+$16.3M
2
EAM
Eventide Asset Management
Massachusetts
+$16.3M
3
FTM
First Turn Management
California
+$11.3M
4
PCH
Polar Capital Holdings
United Kingdom
+$10.3M
5
EP
Eversept Partners
New York
+$10.2M

Top Sellers

1
Wellington Management Group
Wellington Management Group
Massachusetts
-$48.6M
2
SI
Sofinnova Investments
California
-$28.2M
3
APM
Avidity Partners Management
Texas
-$18.2M
4
Marshall Wace
Marshall Wace
United Kingdom
-$17.4M
5
ECM
ExodusPoint Capital Management
New York
-$6.35M
Name Holding Trade Value Shares
Change 		Change in
Stake
GTC
51
Ghost Tree Capital
New York
$8.66M +$2.07M +100,000 +29%
CM
52
Crestline Management
Texas
$8.25M +$5.89M +285,258 +199%
Hudson Bay Capital Management
53
Hudson Bay Capital Management
Connecticut
$8.18M +$8.78M +425,000 New
PHS
54
PFM Health Sciences
California
$8.16M +$755K +36,553 +9%
PAI
55
Palo Alto Investors
California
$7.8M – – –
SCM
56
Silverarc Capital Management
Massachusetts
$7.29M +$181K +8,746 +2%
Balyasny Asset Management
57
Balyasny Asset Management
Illinois
$7.07M +$7.59M +367,177 New
Ensign Peak Advisors
58
Ensign Peak Advisors
Utah
$6.97M -$3.24M -157,060 -30%
D.E. Shaw & Co
59
D.E. Shaw & Co
New York
$6.78M +$4.25M +205,715 +140%
ACM
60
ADAR1 Capital Management
Texas
$6.74M +$7.24M +350,206 New
ECM
61
ExodusPoint Capital Management
New York
$6.13M -$6.35M -307,329 -49%
RPAM
62
Rhenman & Partners Asset Management
Sweden
$5M +$640K +31,000 +14%
Macquarie Group
63
Macquarie Group
Australia
$4.68M +$8.95K +433 +0.2%
Bank of New York Mellon
64
Bank of New York Mellon
New York
$4.26M -$1.45M -70,324 -24%
PCM
65
Peregrine Capital Management
Minnesota
$3.83M +$8.82K +427 +0.2%
TC
66
TwinBeech Capital
New York
$3.82M +$638K +30,865 +18%
Barclays
67
Barclays
United Kingdom
$3.61M +$2.28M +110,535 +143%
SSA
68
Schonfeld Strategic Advisors
New York
$3.61M -$1.52M -73,413 -28%
Rafferty Asset Management
69
Rafferty Asset Management
New York
$3.3M -$132K -6,398 -4%
Susquehanna International Group
70
Susquehanna International Group
Pennsylvania
$3.25M +$1.38M +66,679 +65%
Swiss National Bank
71
Swiss National Bank
Switzerland
$2.88M -$24.8K -1,200 -0.8%
UBS Group
72
UBS Group
Switzerland
$2.82M +$440K +21,286 +17%
UBS AM
73
UBS AM
Illinois
$2.65M -$329K -15,913 -10%
Jane Street
74
Jane Street
New York
$2.57M -$408K -19,770 -13%
PBM
75
Propel Bio Management
California
$2.57M +$1.03M +50,000 +60%
1 2
3
4 5

SNDX Hedge Fund Activity: Q3 2024 in Review

210 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q3 2024, worth a combined $1.71B — down 4.5% from $1.79B a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new SNDX positions and 24 closed out — a net gain of 14 holders — while 86 added to existing stakes and 58 trimmed.

The largest buyer was BNP Paribas Asset Management, opening a new position worth an estimated $16.3M. The largest seller was Wellington Management Group, cutting an estimated $48.6M.

  • 210 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q3 2024, up from 196 in Q2 2024.
  • Funds reported $1.71B of Syndax Pharmaceuticals stock for Q3 2024, down 4.5% quarter-over-quarter.
  • 38 funds opened new Syndax Pharmaceuticals positions in Q3 2024 and 24 closed out, a net change of +14 holders.
  • The largest Syndax Pharmaceuticals buyer in Q3 2024 was BNP Paribas Asset Management, an estimated $16.3M added.
  • The largest Syndax Pharmaceuticals seller in Q3 2024 was Wellington Management Group, an estimated $48.6M sold.

Based on aggregated 13F filings for Q3 2024.